Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

38 results
Display

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer

Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT

OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combination of carboplatin and intermittent normobaric hyperoxia synergistically suppresses benzo[a]pyrene-induced lung cancer

Lee HY, Kim IK, Lee HI, Lee HY, Kang HS, Yeo CD, Kang HH, Moon HS, Lee SH

BACKGROUND/AIMS: We explored the effects of intermittent normobaric hyperoxia alone or combined with chemotherapy on the growth, general morphology, oxidative stress, and apoptosis of benzo[a]pyrene (B[a]P)-induced lung tumors in mice. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

Lee MX, Tan DS

The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic Oncology Group (JGOG) 3016 study demonstrated significant...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

Lee YJ, Kim YM, Lee SW, Park JY, Kim DY, Suh DS, Kim JH, Kim YT, Nam JH

OBJECTIVE: This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) with or without carboplatin in Korean patients with recurrent ovarian cancer (ROC), fallopian tube, or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin

Yazawa H, Hiraiwa T, Ito F, Fujimori K

We describe an extremely rare case of advanced pure primary ovarian squamous cell carcinoma (SCC), treated by adjuvant chemotherapy with dose-dense paclitaxel combined with carboplatin (dd-TC) plus the combination chemotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine

Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ

PURPOSE: There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS: We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan

Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata

OBJECTIVE: To assess the use of colony-stimulating factors (CSFs) in patients with ovarian cancer who receive adjuvant paclitaxel and carboplatin chemotherapy in clinical practice and to assess whether the frequency...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Weekly irinotecan and carboplatin for patients with small cell lung cancer

Lee HW, Jeong EG, Kim DH, Lee H, Kang BH, Um SJ, Roh M, Son C

BACKGROUND: Lung cancer is the most common cause of cancer-related death worldwide and in Korea, and small cell lung cancer (SCLC) is the most deadly tumor type in the different...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Carboplatin, ifosfamide, and etoposide chemotherapy for extensive-disease small cell lung cancer

Ryu HJ, Kim YN, Gyeong SY, Park SH, An CH, Bang SM, Lee SP, Lee JI, Park JU, Cho EK, Jeong SH, Shin DB, Lee JH

  • KMID: 2305976
  • Korean J Med.
  • 2006 Jun;70(6):688-694.
BACKGROUND: This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A phase II study of etoposide (VP-16), ifosfamide, and carboplatin combination chemotherapy plus concurrent thoracic irradiation for limited stage small cell lung cancer

Lee Y, Lee SJ, Kim YN, Lee SH, Kyung SY, Nam E, Park SH, An CH, Bang SM, Lee SP, Park JW, Lee KC, Cho EK, Jeong SH, Shin DB, Lee JH

  • KMID: 1833325
  • Korean J Med.
  • 2006 Apr;70(4):402-409.
BACKGROUND: Small cell lung cancer (SCLC) is very sensitive to both chemotherapy and radiation therapy. In limited disease of SCLC, the addition of radiation therapy to chemotherapy improves survival and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with 10 or more Positive Lymph Nodes: a 5-Year follow-Up Results

Sohn HJ, Kim SH, Lee GW, Kim S, Ahn JH, Kim SB, Kim SW, Kim WK, Suh C

  • KMID: 2270830
  • Cancer Res Treat.
  • 2005 Jun;37(3):137-142.
PURPOSE: The benefit of consolidation high-dose chemotherapy (HDC) for high-risk primary breast cancer is controversial. We evaluated the efficacy and safety of consolidation HDC with cyclophosphamide, thiotepa and carboplatin (CTCb)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result

Sohn HJ, Kim SH, Lee GW, Kim S, Kang HJ, Ahn JH, Kim SB, Kim SW, Kim WK, Suh C

  • KMID: 1743351
  • Cancer Res Treat.
  • 2005 Feb;37(1):24-30.
PURPOSE: The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Concurrent Chemoradiotherapy of Paclitaxel and Carboplatin as Adjuvant Therapy after Primary Surgery in High-risk Cervical Cancer

Cho HI, Kim JW, Park NH, Song YS, Kang SB, Lee HP

  • KMID: 2272338
  • Korean J Obstet Gynecol.
  • 2004 May;47(5):917-923.
OBJECTIVE: To evaluate the efficacy and safety of concurrent chemotherapy of paclitaxel and carboplatin with standard pelvic radiotherapy as adjuvant therapy after primary surgery in high-risk cervical cancer. METHODS: Twenty-eight patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Docetaxel and Carboplatin Combination Chemotherapy against Persistent or Recurrent Ovarian Cancer as 2nd or more line Chemotherapy

Kim YH, Shin HC, Ahn SN, Lee CJ, Kim WG

  • KMID: 2272433
  • Korean J Obstet Gynecol.
  • 2004 Nov;47(11):2123-2130.
OBJECTIVE: We evaluated the effects and toxicities of docetaxel-carboplatin combination chemotherapy against recurrent or persistent ovarian cancer who were previously heavily treated with one or more lines of chemotherapy. METHODS: Sixteen...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Second-line Chemotherapy with Paclitaxel and Carboplatin for Patients with Recurrent Ovarian Carcinoma

Seo HJ, Lee CM, Kim JS, Lee HJ, Park YJ, Cho YK, Choi H, Kim BR, Lee HK

  • KMID: 2272400
  • Korean J Obstet Gynecol.
  • 2004 Oct;47(10):1915-1920.
OBJECTIVE: This study is to investigate the efficacy and toxicity of paclitaxel plus carboplatin used as a salvage therapy. METHODS: Between June 2000 and November 2003, 10 patients aged 43-74 (median...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiple Infarcts after Intra-arterial Carboplatin Therapy

Min JH, Kim JH, Chung YG, Lee NJ, Suh JK, Lee HK

  • KMID: 1955788
  • J Korean Neurosurg Soc.
  • 2003 Sep;34(3):254-257.
We report a case of multiple cerebral infarcts, which developed after intra-arterial(IA) carboplatin therapy in a patient with glioblastoma who had received surgery with conventional and intraoperative radiation therapy (IORT)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Levofloxacin on the Survival of Ovarian Cancer Cells with or Without Carboplatin Under Hypoxic Condition

Hong SY, Park JH, Kim EJ, Lee JW, Koh SB, Lee TS

  • KMID: 2272123
  • Korean J Obstet Gynecol.
  • 2003 Aug;46(8):1517-1524.
In solid tumor, there is a hypoxic region where oxygen supply is insufficient. In this study, we found that one of the quinolone antibiotics, levofloxacin, made a human ovarian cancer...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Features of Hypersensitivity Reactions to Cisplatin and Carboplatin

Park YJ, Moon EJ, Chung HH, Roh JW, Park SY, Park YS

  • KMID: 2272046
  • Korean J Obstet Gynecol.
  • 2003 May;46(5):1018-1023.
OBJECTIVE: To characterize the clinical features of platinum compounds (cisplatin plus carboplatin) associated hypersensitivity reactions. METHODS: Medical records of 102 patients with gynecologic malignancy who received chemotherapy based on platinum at...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Trial of IV Etoposide and Carboplatin and Cyclophosphamide Combination Chemotherapy Against Persistent or Recurrent Ovarian Cancer as 2nd or More Line Chemotherapy

Kim WG, Kim YH

  • KMID: 2272032
  • Korean J Obstet Gynecol.
  • 2003 May;46(5):922-930.
OBJECTIVE: We evaluated the effects and toxicities and cost effectiveness of iv etoposide-carboplatin- cyclophosphamide (ECC) combination chemotherapy against persistent or recurrent ovarian cancer who were previously heavily treated with one...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Response to Etoposide Plus Carboplatin and Topotecan Chemotherapy in Small Cell Lung Cancer

Park KH, Cho GJ, Ju JY, Son CY, Wi JO, Kim KS, Kim YI, Lim SC, Kim YC, Park KO

  • KMID: 2318414
  • Tuberc Respir Dis.
  • 2003 Apr;54(4):415-428.
BACKGROUND: This study assessed the efficacy and toxicity of etoposide and carboplatin(EC) combination regimen as a first line therapy for small cell lung cancer(SCLC), and determined the efficacy and toxicity...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr